Focus on Licensing Option Fees
How much do pharmaceutical in-licensors tend to pay for options to license technology from biotechs?
You may also be interested in...
Novartis thwarts Sun’s efforts to commercialize nilotinib in India, though the Indian firm indicates that its actions are covered under a local Bolar-type provision and that it has no plans to market the oncology drug while the originator's patent stands valid.
Centus Biotherapeutics has received formal European Commission approval for its Equidacent biosimilar rival to Avastin.
The IGBA has called for a “streamlined” global biosimilar development and registration process, with a new policy paper highlighting the limited value of comparative efficacy clinical data at the same time as it urges renewed efforts on educating healthcare professionals.